[
  {
    "id": 191,
    "question": "Long scenario deafness visual issues myoclonus, and also came with stroke MERF. WHAT you will do??",
    "option_a": "NOTCH 3",
    "option_b": "Measure pyruvate / lactate",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nFabry disease is an X\u2010linked lysosomal storage disorder caused by deficient activity of the enzyme \u03b1\u2010galactosidase A. This enzyme deficiency leads to the accumulation of glycosphingolipids, particularly globotriaosylceramide, in various tissues including blood vessel walls, nerves, and skin.\n\n**Pathophysiology**\n\nDue to a mutation in the GLA gene, the decreased activity of \u03b1\u2010galactosidase A results in the progressive deposition of globotriaosylceramide in endothelial cells, nerve cells, and other tissues. This accumulation causes vascular dysfunction, ischemia, and neuropathic pain. It also leads to characteristic skin lesions (angiokeratomas) and can predispose patients to early strokes.\n\n**Clinical Correlation**\n\nThe 14\u2010year\u2010old boy presenting with intense, lancinating pain in the feet and decreased pain sensation, alongside his sister\u2019s milder symptoms and a maternal grandfather with premature stroke, is highly suggestive of Fabry disease. The presence of skin lesions further strengthens the diagnosis since angiokeratomas are a hallmark of the condition.\n\n**Diagnostic Approach**\n\nThe diagnostic workup involves measuring \u03b1\u2010galactosidase A activity in plasma or leukocytes. Differential diagnoses to consider include other neuropathies such as diabetic neuropathy or hereditary sensory neuropathies; however, the combination of neuropathic pain, characteristic angiokeratomas, and a family history of early cerebrovascular events is specific for Fabry disease.\n\n**Management Principles**\n\nManagement initially involves enzyme replacement therapy (ERT) with agents such as agalsidase beta or agalsidase alfa to reduce substrate accumulation. For symptomatic relief, pain management strategies are employed. In addition, regular monitoring for renal, cardiac, and cerebrovascular complications is necessary. In pregnant or lactating women, the decision to initiate ERT must balance maternal benefits against potential risks, with recent guidelines generally supporting its use when indicated.\n\n**Option Analysis**\n\nOption A (\u03b1\u2010Galactosidase activity) is the correct test for diagnosing Fabry disease. Option B (Transferritine) is related to iron metabolism and not relevant here. Option C (VLCFA) is used in the diagnostic workup of peroxisomal disorders like adrenoleukodystrophy. Option D (PME22 gene) pertains to certain hereditary neuropathies and is not applicable in this scenario.\n\n**Clinical Pearls**\n\n1. Fabry disease should be considered in young patients with neuropathic pain and characteristic skin lesions. 2. An X\u2010linked inheritance pattern can lead to variable expression in females. 3. Early enzyme replacement can help mitigate long\u2010term complications such as renal and cerebrovascular disease.\n\n**Current Evidence**\n\nRecent research supports the use of both enzyme replacement therapy and, in certain cases, chaperone therapy (e.g., migalastat) in patients with amenable mutations. Current guidelines stress early diagnosis and intervention to manage systemic complications efficiently.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "id": 192,
    "question": "A 66-year-old male patient presented with dysarthria and right sided weakness for 10 hours. CT brain done and showed acute ischemic change over the the left internal capsule (No attached image).\n\nWhich of the following is the next step in the management?",
    "option_a": "Aspirin",
    "option_b": "Dual antiplatelets",
    "option_c": "IV Labetalol",
    "option_d": "IV Nitroprusside",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nFabry disease is an X\u2010linked lysosomal storage disorder caused by deficient activity of the enzyme \u03b1\u2010galactosidase A. This enzyme deficiency leads to the accumulation of glycosphingolipids, particularly globotriaosylceramide, in various tissues including blood vessel walls, nerves, and skin.\n\n**Pathophysiology**\n\nDue to a mutation in the GLA gene, the decreased activity of \u03b1\u2010galactosidase A results in the progressive deposition of globotriaosylceramide in endothelial cells, nerve cells, and other tissues. This accumulation causes vascular dysfunction, ischemia, and neuropathic pain. It also leads to characteristic skin lesions (angiokeratomas) and can predispose patients to early strokes.\n\n**Clinical Correlation**\n\nThe 14\u2010year\u2010old boy presenting with intense, lancinating pain in the feet and decreased pain sensation, alongside his sister\u2019s milder symptoms and a maternal grandfather with premature stroke, is highly suggestive of Fabry disease. The presence of skin lesions further strengthens the diagnosis since angiokeratomas are a hallmark of the condition.\n\n**Diagnostic Approach**\n\nThe diagnostic workup involves measuring \u03b1\u2010galactosidase A activity in plasma or leukocytes. Differential diagnoses to consider include other neuropathies such as diabetic neuropathy or hereditary sensory neuropathies; however, the combination of neuropathic pain, characteristic angiokeratomas, and a family history of early cerebrovascular events is specific for Fabry disease.\n\n**Management Principles**\n\nManagement initially involves enzyme replacement therapy (ERT) with agents such as agalsidase beta or agalsidase alfa to reduce substrate accumulation. For symptomatic relief, pain management strategies are employed. In addition, regular monitoring for renal, cardiac, and cerebrovascular complications is necessary. In pregnant or lactating women, the decision to initiate ERT must balance maternal benefits against potential risks, with recent guidelines generally supporting its use when indicated.\n\n**Option Analysis**\n\nOption A (\u03b1\u2010Galactosidase activity) is the correct test for diagnosing Fabry disease. Option B (Transferritine) is related to iron metabolism and not relevant here. Option C (VLCFA) is used in the diagnostic workup of peroxisomal disorders like adrenoleukodystrophy. Option D (PME22 gene) pertains to certain hereditary neuropathies and is not applicable in this scenario.\n\n**Clinical Pearls**\n\n1. Fabry disease should be considered in young patients with neuropathic pain and characteristic skin lesions. 2. An X\u2010linked inheritance pattern can lead to variable expression in females. 3. Early enzyme replacement can help mitigate long\u2010term complications such as renal and cerebrovascular disease.\n\n**Current Evidence**\n\nRecent research supports the use of both enzyme replacement therapy and, in certain cases, chaperone therapy (e.g., migalastat) in patients with amenable mutations. Current guidelines stress early diagnosis and intervention to manage systemic complications efficiently.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "id": 193,
    "question": "A 60s-year-old male presented to the ER with 2 days history of unilateral weakness and dysarthria. On examination, BP 170/90, HR 80s. What is the next step in the management?",
    "option_a": "IV labetalol",
    "option_b": "IV nitroprusside",
    "option_c": "Observation",
    "option_d": "Resume home medications",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis case involves an ischemic stroke patient presenting 2 days after symptom onset with moderately elevated blood pressure. In ischemic strokes, especially when the patient is outside the thrombolytic time window, permissive hypertension is generally allowed to ensure adequate cerebral perfusion to the affected areas.\n\n**Pathophysiology**\n\nDuring an ischemic stroke, the brain\u2019s autoregulatory mechanisms may cause blood pressure to rise in an effort to maintain blood flow to the ischemic penumbra. Aggressive blood pressure reduction in this phase can decrease cerebral perfusion, risking expansion of the infarct. Thus, in patients who are not candidates for thrombolysis, blood pressure is often left untreated unless it is extremely high.\n\n**Clinical Correlation**\n\nThe patient presents with unilateral weakness and dysarthria, symptoms typical of a stroke, with blood pressure at 170/90 mmHg. Given that the stroke occurred 2 days ago and the blood pressure is not excessively high, the best approach is to continue supportive care with observation.\n\n**Diagnostic Approach**\n\nWhile imaging (CT/MRI) is essential in stroke evaluation to differentiate between ischemic and hemorrhagic strokes, in this scenario the management focus is on blood pressure. Differential diagnoses include hemorrhagic stroke, stroke mimics, and lacunar infarcts; however, in the subacute phase of ischemia management, aggressive BP control is not indicated unless BP is >220/120 when not undergoing thrombolysis.\n\n**Management Principles**\n\nAccording to current AHA/ASA guidelines, in acute ischemic stroke patients not receiving thrombolysis, blood pressure should not be lowered aggressively unless it exceeds 220/120 mmHg. The tiered management involves supportive care, refraining from precipitous BP reduction, and monitoring. For women who are pregnant or lactating, similar principles apply with careful consideration of medication safety if any pharmacological intervention becomes necessary.\n\n**Option Analysis**\n\nOption A (IV labetalol) and Option B (IV nitroprusside) suggest active blood pressure reduction which is not required at a BP of 170/90 mmHg in this clinical setting. Option D (Resume home medications) does not address the acute scenario adequately. Option C (Observation) is correct as it aligns with the principle of permissive hypertension in ischemic stroke beyond the thrombolysis window.\n\n**Clinical Pearls**\n\n1. Permissive hypertension is a cornerstone of acute ischemic stroke management when patients are not eligible for thrombolysis. 2. The thrombolytic window (typically 4.5 hours) is critical; after that, supportive care is emphasized.\n\n**Current Evidence**\n\nRecent guidelines continue to support a conservative approach to blood pressure management in non-thrombolysis ischemic stroke patients, emphasizing the risk of further ischemia with aggressive BP reductions.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "id": 194,
    "question": "An elderly male presented to the ER with right sided weakness aphasia, Examination showed BP 220/120, HR 90s, patient was drowsy, aphasic, with right sided weakness NIHSS high (not sure about the number). What is the next step in management?",
    "option_a": "CT brain",
    "option_b": "Control Blood pressure",
    "option_c": "IV thrombolysis",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn the acute management of stroke, neuroimaging is the cornerstone to differentiate between ischemic and hemorrhagic etiologies. A prompt CT scan is critical in establishing the diagnosis and guiding subsequent interventions.\n\n**Pathophysiology**\n\nMarkedly elevated blood pressure, as seen with 220/120 mmHg, increases the risk of hemorrhagic transformation and intracerebral bleeding. However, in the context of ischemic stroke, high blood pressure may be a compensatory mechanism to maintain perfusion to the penumbra. Knowing the stroke subtype through imaging is essential before any treatment decisions.\n\n**Clinical Correlation**\n\nThis elderly male exhibits classic stroke symptoms (right-sided weakness and aphasia) with a high NIHSS score and severely elevated BP. The clinical severity and high blood pressure necessitate immediate imaging to exclude hemorrhage.\n\n**Diagnostic Approach**\n\nDifferential diagnosis includes acute ischemic stroke, intracerebral hemorrhage, and stroke mimics. Computed tomography (CT) of the brain is the first-line diagnostic tool because it rapidly distinguishes hemorrhagic from ischemic stroke, which is critical for subsequent management decisions such as thrombolysis.\n\n**Management Principles**\n\nCurrent guidelines recommend immediate CT imaging in suspected stroke cases. For patients with ischemic stroke and a history suggesting possible thrombolysis, blood pressure must be lowered to below 185/110 mmHg before IV thrombolysis can be initiated. However, the decision to control blood pressure comes after the imaging has confirmed the absence of hemorrhage.\n\n**Option Analysis**\n\nOption A (CT brain) is correct because it confirms the diagnosis and rules out hemorrhage. Option B (Control Blood pressure) is an important step but should be undertaken after imaging confirms the type of stroke and when considering thrombolytic therapy. Option C (IV thrombolysis) cannot be administered without diagnostic imaging and addressing the blood pressure issue first.\n\n**Clinical Pearls**\n\n1. 'Time is brain' \u2013 rapid imaging with CT is essential in suspected stroke cases. 2. Blood pressure management in stroke is nuanced; it is lowered only if thrombolysis is pursued after confirming ischemia.\n\n**Current Evidence**\n\nRecent AHA/ASA updates reinforce the protocol of immediate CT imaging in acute stroke to guide timely treatment, especially in patients with elevated BP where the risk of hemorrhage is a concern.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "id": 195,
    "question": "Female patient with ESRD on regular hemodialysis complaining of recurrent TIAs last for less than 10 minutes inform of left sided weakness and dysarthria then resolved completely. These symptoms occur during the dialysis sessions. CT brain done and showed evidence of old ischemic stroke. Carotid US done and showed left ICA atherosclerotic changes with no visualized stenosis or occlusion.\nWhich of the following is important to order during evaluation of this patient?",
    "option_a": "CT angiography",
    "option_b": "MRI brain",
    "option_c": "CT Venogram",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nTransient ischemic attacks (TIAs) are brief episodes of neurological dysfunction resulting from transient cerebral ischemia. Recurrent TIAs warrant further vascular investigation to identify any clinically significant vessel disease.\n\n**Pathophysiology**\n\nPatients with ESRD on hemodialysis are at higher risk for vascular calcification and atherosclerotic changes. Additionally, hemodynamic fluctuations during dialysis can precipitate transient episodes of cerebral hypoperfusion, leading to TIAs. Carotid ultrasound may not fully evaluate intracranial vessels, hence additional imaging is required.\n\n**Clinical Correlation**\n\nThis female patient experiences recurrent episodes of left-sided weakness and dysarthria during dialysis sessions. The presence of old ischemic changes on CT supports underlying cerebrovascular disease. While carotid ultrasound shows atherosclerotic changes without significant stenosis, the possibility of intracranial involvement or subtler vascular anomalies necessitates further evaluation.\n\n**Diagnostic Approach**\n\nThe differential diagnosis includes TIA due to embolic phenomena, hemodynamic instability causing global or watershed cerebral ischemia, and intracranial stenosis. CT angiography (CTA) is the non-invasive imaging modality of choice for evaluating both cervical and intracranial vasculature in this setting.\n\n**Management Principles**\n\nFor patients with TIA, the current guidelines recommend antiplatelet therapy, risk factor modification, and prompt vascular imaging (such as CTA) to evaluate for stenosis or other vascular abnormalities. In ESRD patients, contrast use requires careful consideration, and alternative imaging strategies may be considered if there are concerns regarding contrast-induced nephropathy, though in dialysis patients this is generally less concerning. For pregnant or lactating patients, the use of contrast is approached with caution and benefits weighed against potential risks.\n\n**Option Analysis**\n\nOption A (CT angiography) is correct as it provides detailed visualization of the entire cerebrovascular tree, helping to identify lesions that may not be apparent on carotid ultrasound. Option B (MRI brain) is better for tissue characterization and detecting small infarcts but is less optimal for evaluating vascular anatomy in this context. Option C (CT Venogram) is not indicated as the clinical scenario does not suggest a venous pathology.\n\n**Clinical Pearls**\n\n1. Recurrent TIAs are a red flag for impending stroke, necessitating comprehensive vascular evaluation. 2. In ESRD patients, hemodynamic shifts during dialysis can precipitate cerebral ischemia, making timely vascular imaging crucial.\n\n**Current Evidence**\n\nRecent studies underscore the utility of CT angiography in TIA workups, as it can swiftly detect both extracranial and intracranial vascular pathologies that might be missed by ultrasound alone.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "id": 196,
    "question": "Female patient came with ischemic stroke, history of previous 2 abortions, elevated prothrombin time. What is the most helpful investigation in her case?",
    "option_a": "Anti phospholipid syndrome",
    "option_b": "Prothrombin Gene Mutation",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAntiphospholipid syndrome (APS) is an autoimmune thrombophilic disorder that manifests with both arterial and venous thromboses and recurrent pregnancy losses. It represents one of the key causes of ischemic stroke in young to middle-aged women, especially when accompanied by a history of miscarriages.\n\n**Pathophysiology**\n\nAPS is characterized by the presence of antiphospholipid antibodies (such as anticardiolipin antibodies, lupus anticoagulant, and anti-\u03b22 glycoprotein I) which lead to a hypercoagulable state. These antibodies disrupt normal coagulation processes, paradoxically prolonging clotting times in laboratory assays while predisposing patients to thrombosis. This explains the association with both elevated clotting times and thrombotic events.\n\n**Clinical Correlation**\n\nA female patient with an ischemic stroke, a history of recurrent miscarriages, and abnormal coagulation tests is highly suggestive of APS. The clinical picture differentiates APS from other thrombophilias, such as prothrombin gene mutation, which does not commonly present with recurrent abortions.\n\n**Diagnostic Approach**\n\nThe diagnostic workup for APS involves laboratory testing for lupus anticoagulant, anticardiolipin antibodies, and anti-\u03b22 glycoprotein I. For a definitive diagnosis, these tests need to be positive on two separate occasions at least 12 weeks apart. Differential diagnoses include other inherited thrombophilias (such as factor V Leiden or prothrombin gene mutation), but the obstetric history specifically points toward APS.\n\n**Management Principles**\n\nIn patients diagnosed with APS, long-term anticoagulation (typically with warfarin aiming for an INR of 2.0-3.0) is recommended for secondary stroke prevention. During pregnancy, warfarin is contraindicated due to teratogenic effects; instead, a regimen of low molecular weight heparin and low-dose aspirin is used. These management strategies are supported even in lactating patients, with special considerations given to the safety profiles of the medications.\n\n**Option Analysis**\n\nOption A (Anti phospholipid syndrome testing) is correct because it directly addresses the suspected diagnosis given the patient\u2019s history of recurrent abortions and ischemic stroke. Option B (Prothrombin Gene Mutation) is less appropriate for this clinical picture, as this mutation is not typically associated with recurrent pregnancy losses.\n\n**Clinical Pearls**\n\n1. APS should be considered in any young woman with thrombotic events and a history of miscarriages. 2. Laboratory testing for APS requires confirmation on two occasions to fulfill diagnostic criteria.\n\n**Current Evidence**\n\nRecent guidelines stress the importance of early APS detection through standardized antibody testing, and they advocate for aggressive, individualized anticoagulation management to reduce the risk of recurrent thrombotic events.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "id": 197,
    "question": "A 30-year-old healthy women presented with 10 days history of severe headache, blurred vision and new onset symptomatic seizure. Neurological examination was unremarkable. Vitaly stable.\n\nCT brain done (image attached).\n\nWhich of the following is the best diagnostic test?",
    "option_a": "MRI brain",
    "option_b": "CT angiogram.",
    "option_c": "CT venogram",
    "option_d": "Lumbar puncture",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question concerns a young woman with a subacute presentation of headache, blurred vision, and new\u2010onset seizure \u2013 a constellation that should raise suspicion for cerebral venous sinus thrombosis (CVT). The core concept is that CVT often presents with signs of raised intracranial pressure and seizures in a young patient (often women, sometimes with risk factors like OCP use or pregnancy), and the imaging choice should best visualize the venous system.\n\n**Pathophysiology**\n\nCVT occurs when a thrombus occludes one or more of the cerebral venous sinuses. This results in impaired venous drainage, increased intracranial pressure, and potentially venous infarction or hemorrhagic conversion. The disruption of venous flow leads to leakage, edema, and sometimes localized seizures. Up\u2010to\u2010date research emphasizes early detection as prompt anticoagulation can minimize permanent damage.\n\n**Clinical Correlation**\n\nThe patient\u2019s headache, blurred vision (often a sign of papilledema secondary to raised ICP), and seizure are typical clinical manifestations of CVT. Despite a normal neurological exam, the subacute nature of symptoms in a young woman without classic risk factors for arterial stroke shifts concern to a venous process.\n\n**Diagnostic Approach**\n\nCommon differentials include subarachnoid hemorrhage, idiopathic intracranial hypertension, and even demyelinating lesions. However, CVT should be differentiated by using imaging modalities that visualize the venous sinuses. Although MRI brain (sometimes with MR venography) is highly sensitive, in acute settings CT venography is both rapid and effective. CT angiogram focuses on arteries and lumbar puncture can be contraindicated in patients with increased intracranial pressure.\n\n**Management Principles**\n\nImmediate management involves anticoagulation (typically with low molecular weight heparin), even in the presence of small hemorrhagic infarcts. According to current guidelines, supportive measures to reduce intracranial pressure and seizure control are also important. In pregnant or lactating patients, unfractionated heparin or LMWH remains the treatment of choice as they do not cross the placenta and are compatible with breastfeeding.\n\n**Option Analysis**\n\nOption A (MRI brain) is useful but may not adequately evaluate the venous system without specialized sequences (i.e., MR venography). Option B (CT angiogram) focuses on arterial rather than venous circulation. Option D (Lumbar puncture) can be dangerous in suspected increased ICP and does not diagnose CVT. Option C (CT venogram) is the best study to visualize the cerebral venous sinuses in an acute setting.\n\n**Clinical Pearls**\n\n1. CVT should be suspected in young women with headaches, seizures, and visual changes even if the neurological exam is unremarkable. 2. CT venogram is a rapid, sensitive imaging modality for assessing the cerebral venous sinuses. 3. Early anticoagulation is critical even in the presence of hemorrhagic lesions.\n\n**Current Evidence**\n\nRecent studies and guidelines continue to support the use of CT venography as a first\u2010line diagnostic tool in suspected CVT. There is also an emphasis on early diagnosis and treatment with heparin anticoagulation, with adaptations made for special populations like pregnant and lactating women.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "id": 198,
    "question": "Patient presented with acute limb weakness and dysarthria. CT brain done and was normal. He was within the window and IV t-PA started. 20 minutes later the primary nurse called the physician as the patient has abnormal swelling around the mouth (imaged attached). Blood pressure was normal.\n\nWhich of the following is the most likely associated risk factor for this condition?",
    "option_a": "Frontal lobe stroke",
    "option_b": "ACE inhibitor",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question addresses a known adverse effect of intravenous thrombolysis (t-PA) used for acute ischemic stroke \u2013 specifically, orolingual angioedema. The core concept is recognizing that t-PA can trigger angioedema, especially in patients taking ACE inhibitors.\n\n**Pathophysiology**\n\nt-PA facilitates the conversion of plasminogen to plasmin, which can lead to the activation of the kallikrein-kinin system and subsequent release of bradykinin. Bradykinin accumulation increases vascular permeability. In patients on ACE inhibitors, the degradation of bradykinin is reduced, further enhancing the risk of angioedema.\n\n**Clinical Correlation**\n\nThe appearance of abnormal swelling around the mouth 20 minutes after initiation of IV t-PA in a patient with normal blood pressure is characteristic of orolingual angioedema. This reaction is often localized to the lips, tongue, or oropharyngeal tissues and can progress to airway compromise if not recognized and managed promptly.\n\n**Diagnostic Approach**\n\nThe diagnosis is clinical; one differentiates this condition from other allergic reactions by its rapid onset following t-PA administration and its predilection for the orolingual region. The history of ACE inhibitor use is a critical associated risk factor distinguishing it from other causes of allergic or angioedematous reactions.\n\n**Management Principles**\n\nImmediate management involves addressing airway concerns followed by pharmacologic therapy. Guidelines suggest administering antihistamines (e.g., diphenhydramine) and steroids, and if necessary, epinephrine. In patients with mild symptoms and stable airway, conservative management with antihistamines is indicated. It is also important to note that ACE inhibitors are contraindicated during pregnancy due to teratogenicity, and this adverse effect is an additional reason to avoid them in pregnant women.\n\n**Option Analysis**\n\nOption A (Frontal lobe stroke) is unrelated to the development of angioedema. The marked answer, Option B (ACE inhibitor), is correct because the use of ACE inhibitors predisposes patients to t-PA induced orolingual angioedema by impairing bradykinin breakdown. Other unspecified options do not pertain to the risk factors for this reaction.\n\n**Clinical Pearls**\n\n1. t-PA-associated angioedema typically occurs within an hour of administration. 2. Concomitant use of ACE inhibitors significantly increases the risk of developing this adverse reaction. 3. Recognizing this complication early is essential to prevent airway compromise.\n\n**Current Evidence**\n\nNewer studies reinforce the association between ACE inhibitors and increased risk of orolingual angioedema with t-PA. Protocols now emphasize early identification and rapid management of this complication, especially in patients known to be taking ACE inhibitors.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "id": 199,
    "question": "Patient presented with acute limb weakness and dysarthria. CT brain done and was normal. He was within the window and IV t-PA started. 20 minutes later the primary nurse called the physician as the patient has abnormal swelling around the mouth (imaged attached). Blood pressure was normal.\n\nWhich of the following is the appropriate next step?",
    "option_a": "Stop t-PA",
    "option_b": "Diphenhydramine",
    "option_c": "Immediate intubation",
    "option_d": "CT brain",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn this scenario, the patient receiving IV t-PA for acute ischemic stroke develops orolingual angioedema shortly thereafter. The key concept is recognizing the complication and instituting appropriate management without unnecessarily interrupting stroke treatment unless airway compromise is imminent.\n\n**Pathophysiology**\n\nIV t-PA can trigger the release of bradykinin through the activation of the kallikrein-kinin pathway. Elevated bradykinin levels increase vascular permeability, leading to angioedema. This is particularly common in patients on ACE inhibitors, where bradykinin degradation is impaired.\n\n**Clinical Correlation**\n\nThe patient\u2019s development of swelling around the mouth\u2014an area highly susceptible to bradykinin effects\u2014despite normal blood pressure, points toward an angioedema reaction rather than a hypertensive bleed or other complication. The clinical picture is consistent with a localized, non-life-threatening adverse reaction that, if not progressing to airway compromise, can be managed medically.\n\n**Diagnostic Approach**\n\nThe diagnosis is clinical, based on the temporal relationship with t-PA infusion and examination of the orofacial region. Differential diagnoses include anaphylaxis from other agents; however, the presence of orolingual swelling without hypotension or diffuse skin involvement supports a localized reaction.\n\n**Management Principles**\n\nThe first step in management for patients with mild to moderate orolingual angioedema is to administer antihistamines such as diphenhydramine. Corticosteroids may also be used. Airway monitoring is essential, and while discontinuing t-PA may be considered in severe cases or if the airway is compromised, mild reactions can often be managed without stopping thrombolytic therapy. In cases of progression to airway compromise, immediate airway protection measures, including intubation, should be instituted. In pregnant or lactating women, diphenhydramine remains the first-line agent as it is considered relatively safe.\n\n**Option Analysis**\n\nOption A (Stop t-PA) might be considered if the angioedema were severe or causing airway compromise; however, in a stable patient with localized swelling, stopping t-PA is not immediately necessary. Option C (Immediate intubation) is reserved for patients with overt airway compromise. Option D (CT brain) is not indicated in this scenario. The marked answer, Option B (Diphenhydramine), is correct as it targets the allergic reaction and is the appropriate immediate management step for mild to moderate symptoms.\n\n**Clinical Pearls**\n\n1. Orolingual angioedema following t-PA does not automatically warrant cessation of thrombolytic therapy if the airway remains secure. 2. Early intervention with antihistamines can arrest the progression of swelling. 3. Always monitor the airway closely, as angioedema can progress rapidly.\n\n**Current Evidence**\n\nRecent guidelines advocate for rapid assessment of airway compromise in t-PA-induced angioedema and recommend medical management with antihistamines and steroids before considering more invasive measures. Studies support that early intervention with agents like diphenhydramine can be effective in controlling mild reactions.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "id": 200,
    "question": "Patient presented to the ER with vertigo and vomiting, What is the feature that can differentiate peripheral from central cause of vertigo?",
    "option_a": "Severe nausea and vomiting",
    "option_b": "Reproducible vertigo",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThe question differentiates the etiologies of vertigo by asking which feature helps distinguish a peripheral from a central cause. The core concept is that peripheral vertigo, often stemming from inner ear disorders such as benign paroxysmal positional vertigo (BPPV) or vestibular neuritis, tends to be elicited by specific head movements or positions.\n\n**Pathophysiology**\n\nPeripheral vertigo arises from pathology in the vestibular apparatus of the inner ear. In conditions like BPPV, displaced otoliths trigger vertigo when the head is moved into certain positions. Conversely, central vertigo is due to lesions in the brainstem or cerebellum (often vascular or demyelinating), where symptoms are less typically tied to positional changes.\n\n**Clinical Correlation**\n\nPatients with peripheral vertigo often experience episodic vertigo that is reproducible with positional maneuvers (e.g., Dix-Hallpike test), and may also have associated tinnitus or hearing loss. In contrast, central vertigo may present with additional neurological signs (e.g., diplopia, dysarthria) and is less reliably elicited by maneuvers.\n\n**Diagnostic Approach**\n\nWhen evaluating vertigo, differential diagnoses include peripheral causes such as BPPV, M\u00e9ni\u00e8re\u2019s disease, and vestibular neuritis, versus central causes such as cerebellar infarction, multiple sclerosis, or brainstem tumors. A detailed history and physical exam (including the head impulse test, positional testing, and evaluation for neurological deficits) help differentiate these conditions.\n\n**Management Principles**\n\nManagement of peripheral vertigo involves maneuvers such as the Epley or Semont maneuvers for BPPV, vestibular rehabilitation for other vestibular disorders, and symptomatic control with vestibular suppressants. In central vertigo, management is directed at the underlying cause (e.g., stroke management protocols). In pregnant or lactating patients, nonpharmacologic measures and repositioning maneuvers are preferred due to medication safety profiles.\n\n**Option Analysis**\n\nOption A (Severe nausea and vomiting) can occur in both peripheral and central vertigo and is not sufficiently discriminatory. The marked answer, Option B (Reproducible vertigo), is correct because in peripheral causes, vertigo can typically be reproduced with specific maneuvers (e.g., Dix-Hallpike), whereas central vertigo is less likely to be triggered reliably by positional changes. The other options were not provided, but among the choices given, reproducibility points toward a peripheral origin.\n\n**Clinical Pearls**\n\n1. In peripheral vertigo, symptoms are often positional and can be reproduced with maneuvers, whereas central vertigo may present with additional focal neurological deficits. 2. The presence of auditory symptoms (tinnitus, hearing loss) alongside vertigo supports a peripheral cause. 3. A normal head impulse test favors a central etiology.\n\n**Current Evidence**\n\nRecent research reinforces that reproducible vertigo with positional changes is a hallmark of peripheral vestibular disorders. Moreover, guideline updates stress the importance of a focused neurological exam (including the HINTS exam) to rule out central causes, especially when the clinical picture is ambiguous.",
    "exam_year": "2023",
    "exam_type": "Part I"
  }
]